IC-P1-024: Depression and hippocampal volumes in a large population-based cohort of elderly people at risk of Alzheimer's disease

2008 ◽  
Vol 4 ◽  
pp. T18-T18
Author(s):  
Mirjam I. Geerlings ◽  
Nicole Schupf ◽  
Truman R. Brown ◽  
Scott A. Small
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
At Risk ◽  
Elderly People ◽  
Large Population ◽  
Population Based

Detection of dementia of the Alzheimer type in a population-based sample: Neuropsychological test performance

1995 ◽  
Vol 1 (3) ◽  
pp. 252-260 ◽  
Author(s):  
Deborah A. Cahn ◽  
David P. Salmon ◽  
Nelson Butters ◽  
Wigbert C. Wiederholt ◽  
Jody Corey-Bloom ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
At Risk ◽  
Test Performance ◽  
Logistic Model ◽  
Neuropsychological Test ◽  
Population Based ◽  
Community Dwelling ◽  
Elderly Subjects ◽  
Alzheimer Type

AbstractThe ability to detect dementia of the Alzheimer type (DAT) in a community-dwelling sample of elderly individuals on the basis of neuropsychological test performance was examined. Three hundred sixty community-dwelling individuals were identified by neurological examination as having probable or possible Alzheimer’s disease, being at risk for Alzheimer’s disease, or having no cognitive impairment. A logistic model comprised of tests of verbal and nonverbal memory, mental flexibility, and confrontation naming correctly classified 82% of DAT subjects and 98% of normal elderly subjects. The logistic model classified 77% of subjects who were diagnosed as at risk for Alzheimer's disease as being cognitively normal. A cross-validation with a clinically based sample of subjects correctly classified 89% of DAT patients and 100% of normal control subjects. The results suggest that psychometric discrimination of dementia may be less accurate in community-dwelling populations than in clinically based samples. (JINS, 1995, I, 252–260.)

scholarly journals Association Between Serum Magnesium Levels and Alzheimer’s Disease or Mixed Dementia Patients: A Population-Based Retrospective Controlled Study

2020 ◽  
Vol 4 (1) ◽  
pp. 399-404
Author(s):  
Sara Ben Zaken ◽  
Zorian Radomysky ◽  
Gideon Koren
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Serum Magnesium ◽  
Large Population ◽  
Population Based ◽  
Controlled Study ◽  
Control Group ◽  
Mixed Dementia ◽  
Dementia Patients ◽  
Increased Risk

Background: High magnesium intake has been associated with a decreased risk of dementia. In contrast, other research has found that both low and high serum magnesium levels were associated with an increased risk of Alzheimer’s disease and mixed dementia. Hence, presently the role of magnesium levels in dementia is unclear. Objective: To investigate a possible association between serum magnesium concentrations and dementia in a large population-based sample. Methods: Maccabi Healthcare Service in Israel provides healthcare to over 2 million citizens. Maccabi maintains a registry with approximately 26,000 diagnosed dementia patients. We focused on patients of both sexes with Alzheimer’s disease or mixed dementia aged 65 or older, excluding patients with clinical diagnoses that could affect serum magnesium level, or with other causes of cognitive decline. Our control group consisted of patients of the same age and sex without dementia. Results: No significant differences were found in mean, mode, and median magnesium levels between the dementia and control groups. However, there were marginally but significantly more cases with low magnesium levels among dementia patients than among controls: A total of 9.4% of tests done in patients with dementia and 7.81% done in non-dementia subjects were hypomagnesemic (p <  0.00001). Conclusion: Despite similar means and medians of serum magnesium in dementia and controls, the proportion of lower than normal magnesium test results was slightly higher among dementia patients. It is possible that patients with dementia have more episodes of hypomagnesemia than controls, despite similar overall mean levels of magnesium.

The Role of Neuroimaging in Fall Prevention in Healthy Adults at Risk of Alzheimer's Disease

2021 ◽  
pp. 107-129
Author(s):  
Albert Dayor Piersson ◽  
Wiam Elshami ◽  
Alberta Naa Afia Adjei ◽  
Klenam Dzefi-Tettey ◽  
Philip N. Gorleku
Keyword(s):  
Public Health ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
At Risk ◽  
Elderly People ◽  
Adult Population ◽  
Critical Role ◽  
Public Health Problem ◽  
The Elderly ◽  
Preclinical Phase

Falls are an important clinical, socioeconomic, and public health problem in the older adult population. Advancing age is a major risk factor for mild cognitive impairment (MCI) and Alzheimer's disease (AD). The preclinical phase of AD, which is regarded as an important window for early therapeutic intervention before the onset of MCI and subsequently AD, can serve as a critical period to reduce or prevent falls among elderly people at risk of AD. In this chapter, first, a discussion is provided on the degrees of fall-related injuries, pain, and severity of falls in elderly people at risk of AD. Secondly, a discussion is provided on the clinical, socioeconomic, and public health implications of falls. Studies that integrated neuroimaging techniques were also reviewed to identify brain biomarkers that can be targeted for the prevention of falls among the elderly. It is anticipated that the outcome of this chapter may have a critical role in the prevention of falls among elderly people at risk or suffering from AD.

The Modulatory Effect of Sex on the Association between APOE and Neuropsychiatric Symptom Burden in Older Adults at Risk for Alzheimer's Disease.

2021 ◽  
Vol 29 (4) ◽  
pp. S51
Author(s):  
Andrew Dissanayake ◽  
Cristopher R. Bowie ◽  
Meryl A. Butters ◽  
Alastair Flint ◽  
Damien Gallagher ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Older Adults ◽  
Alzheimer's Disease ◽  
At Risk ◽  
Symptom Burden ◽  
Neuropsychiatric Symptom

scholarly journals Cognitive Performance and Cerebrospinal Fluid Markers in Preclinical Alzheimer’s Disease: Results from the Gothenburg H70 Birth Cohort Studies

2021 ◽  
Vol 79 (1) ◽  
pp. 225-235
Author(s):  
Maya Arvidsson Rådestig ◽  
Johan Skoog ◽  
Henrik Zetterberg ◽  
Jürgen Kern ◽  
Anna Zettergren ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebrospinal Fluid ◽  
Cohort Studies ◽  
Cognitive Performance ◽  
Birth Cohort ◽  
Population Based ◽  
Tau Pathology ◽  
Preclinical Alzheimer’S Disease ◽  
Preclinical Ad

Background: We have previously shown that older adults with preclinical Alzheimer’s disease (AD) pathology in cerebrospinal fluid (CSF) had slightly worse performance in Mini-Mental State Examination (MMSE) than participants without preclinical AD pathology. Objective: We therefore aimed to compare performance on neurocognitive tests in a population-based sample of 70-year-olds with and without CSF AD pathology. Methods: The sample was derived from the population-based Gothenburg H70 Birth Cohort Studies in Sweden. Participants (n = 316, 70 years old) underwent comprehensive cognitive examinations, and CSF Aβ-42, Aβ-40, T-tau, and P-tau concentrations were measured. Participants were classified according to the ATN system, and according to their Clinical Dementia Rating (CDR) score. Cognitive performance was examined in the CSF amyloid, tau, and neurodegeneration (ATN) categories. Results: Among participants with CDR 0 (n = 259), those with amyloid (A+) and/or tau pathology (T+, N+) showed similar performance on most cognitive tests compared to participants with A-T-N-. Participants with A-T-N+ performed worse in memory (Supra span (p = 0.003), object Delayed (p = 0.042) and Immediate recall (p = 0.033)). Among participants with CDR 0.5 (n = 57), those with amyloid pathology (A+) scored worse in category fluency (p = 0.003). Conclusion: Cognitively normal participants with amyloid and/or tau pathology performed similarly to those without any biomarker evidence of preclinical AD in most cognitive domains, with the exception of slightly poorer memory performance in A-T-N+. Our study suggests that preclinical AD biomarkers are altered before cognitive decline.

P2-230: Modeling the longitudinal atrophy in healthy subject at risk for Alzheimer's disease

2012 ◽  
Vol 8 (4S_Part_9) ◽  
pp. P340-P340
Author(s):  
Marco Lorenzi ◽  
Giovanni Frisoni ◽  
Nicholas Ayache ◽  
Xavier Pennec
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
At Risk ◽  
Healthy Subject
Sign in / Sign up

Export Citation Format

Share Document